[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616059":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":40,"collaborators":42,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":20,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University College, London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous anti-CCR9 CAR T cells","EXPERIMENTAL","Patients will receive autologous anti-CCR9 CAR T cells intravenously.",[13],"Biological: CARCCR9 T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CARCCR9 T cells","Anti-CCR9 CAR T cells",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"FRACTALL Trial Manager","CONTACT","+44 (0)20 76705748","ctc.fractall@ucl.ac.uk",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":20},"University College London Hospitals","RECRUITING","London","United Kingdom","UK",{"type":35,"coordinates":36},"Point",[37,38],-0.12574,51.50853,{"lat":38,"lon":37},{"type":41,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[43,46],{"name":44,"class":45},"Great Ormond Street Hospital Charity","UNKNOWN",{"name":47,"class":48},"Medical Research Council","OTHER_GOV","100616059","phase-1-anti-ccr9-car-t-cells-for-t-cell-leukaemialymphoma-100616059",false,"NCT07300683","Anti-CCR9 CAR T Cells for T Cell Leukaemia\u002FLymphoma","Fratricide-Resistant Autologous Chimeric Antigen Receptor T Cells Targeting CCR9 for the Treatment of T Cell Acute Lymphoblastic Leukaemia\u002F Lymphoma","FRACTALL","Key Inclusion Criteria:\n\n* Relapsed or refractory T-ALL\u002FT-LBL following at least one (≥18 years old) or two (\\\u003C18 years old) standard prior lines of combination cytotoxic therapy\n* CCR9-positive disease as assessed by flow cytometry\n* T-LBL patients only: Patients must have measurable disease\n* Agreement to have a pregnancy test, use adequate contraception (if applicable)\n* Written informed consent\n\nKey Exclusion Criteria:\n\n* ECOG performance score \\>2 (patients aged ≥10 years old) OR Lanksy score ≤50% (patients aged \\\u003C10 years old)\n* Stem Cell Transplant patients only: active significant acute GvHD or moderate\u002Fsevere chronic GvHD requiring immunosuppressive therapy and\u002For systemic steroids\n* Active CNS involvement of disease\n* Active hepatitis B, C or HIV infection\n* Oxygen saturation ≤90% on air\n* Bilirubin \\>3 x upper limit of normal\n* GFR \\\u003C30 ml\u002Fmin\n* Cardiac dysfunction\n* Patients receiving corticosteroids at a supraphysiological dose that cannot be discontinued\n* Known allergy to any component of the ATIMP\n* Any contraindications to lymphodepletion or to the use of cyclophosphamide or fludarabine as per local SmPC\n* Women who are pregnant or breastfeeding\n* Life expectancy \\\u003C3 months\n* Fulminant or rapidly progressive disease","ALL",{"count":59,"type":60},24,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma.\n\nParticipants will:\n\n* have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory.\n* be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells.\n* be given the CAR T cells into their vein.\n* stay in the hospital for a minimum of 2 weeks to be closely monitored\n* following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years)\n* during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and\u002For imaging tests (CT\u002FPET-CT scans) depending on their type of T-cell cancer.",[66,67],"T Cell Acute Lymphoblastic Leukemia","T Cell Lymphoblastic Lymphoma",[55,69,70,71],"Fratricide-Resistant","CCR9","CAR T cells","2025-12-17",{"date":74,"type":75},"2025-12-24","ACTUAL",{"date":77,"type":75},"2025-11-11",{"date":79,"type":60},"2042-12",{"name":5,"class":6},1]